• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

    4/17/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email

    – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases –

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.

    "Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines and accelerating growth for companies as they transition to the commercial stage," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "Jason's experience building and leading teams, particularly in the area of rare disease, comes at the perfect time for Stoke as we plan for our registrational study of STK-001 and set our sights on the future where we aim to deliver the first potential disease-modifying medicine to patients with Dravet syndrome."

    "The recent data from the studies of STK-001 suggest that Stoke has the opportunity to change the way Dravet syndrome is treated by targeting the underlying cause of the disease, not just the symptoms," said Mr. Hoitt. "I have been fortunate to have worked on some incredibly important advances in the treatment of severe diseases and look forward to bringing that experience and passion to Stoke. I am excited by the opportunity to build on the strong foundation of scientific innovation and clinical execution as we prepare the company to successfully conduct a registrational study and commercialize STK-001 and other potential new medicines in the future."

    Prior to joining Stoke, Mr. Hoitt served as Chief Commercial Officer at Provention Bio and led all commercial efforts including pre-launch and launch strategy and execution for Tzield® (teplizumab-mzwv), the first drug approved to address the underlying autoimmune cause of type 1 diabetes. Prior to Provention Bio, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals and led all commercial efforts including launch strategy and execution for DOPTELET® (avatrombopag) for chronic immune thrombocytopenia. Prior to Dova Pharmaceuticals, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales. Mr. Hoitt also held senior sales, marketing and medical affairs roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences. Mr. Hoitt has held integral roles in the launch of several innovative medicines, including Arikayce (Insmed), Exondys 51 (Sarepta), and Incivek (Vertex). Mr. Hoitt holds a B.A. from the College of the Holy Cross.

    Effective on April 15, 2024, Stoke granted Mr. Hoitt a stock option to purchase an aggregate of 265,000 shares of common stock, as a material inducement to his employment in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock option that was granted has an exercise price of $12.21 per share, which is equal to the closing price of Stoke's common stock on April 15, 2024. The option will vest over a 4-year period, with 1/4th of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the option over the following 36 months, subject to Mr. Hoitt's continued employment with Stoke on such vesting dates. The option has a term of 10 years and is subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

    About Stoke Therapeutics

    Stoke Therapeutics (NASDAQ:STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the ability of STK-001 to treat the underlying cause of Dravet syndrome, and the timing and expected progress of clinical trials, regulatory decisions and successful development of STK-001. Statements including words such as "will," "expect," "plan," and "potential" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including STK-001; positive results in a clinical trial may not be replicated in subsequent trials; successes in early stage trials may not be predictive of results in later stage trials; the Company's ability to fund development activities and achieve development goals; and other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, its quarterly reports on Form 10-Q, and the other documents it files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240417733047/en/

    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The

      4/1/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syn

      3/18/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Announces CEO Transition

      Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Offi

      3/18/25 6:58:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

      – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

      9/4/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

      – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

      4/17/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Ian Smith to its Board of Directors

      – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

      9/20/23 4:30:00 PM ET
      $FHTX
      $SLDB
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $STOK
    SEC Filings

    See more
    • CHIEF MEDICAL OFFICER Ticho Barry sold $266,953 worth of shares (26,631 units at $10.02), decreasing direct ownership by 44% to 33,998 units (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      5/5/25 4:08:50 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levin Arthur A converted options into 1,210 shares (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      4/2/25 4:03:15 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim CEO Smith Ian F

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      3/20/25 6:19:44 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:58 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Stoke Therapeutics Inc.

      SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 4:24:49 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:12 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Stoke Therapeutics Inc.

      144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

      5/1/25 4:45:41 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Stoke Therapeutics Inc.

      DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:06:17 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Stoke Therapeutics Inc.

      DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:05:27 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of zorevunersen will evaluate reductions in major motor seizure frequency as well as improvements in behavior and cognition in children and adolescents ages 2 to <18 years old – – FDA Breakthrough Therapy designation positions zorevunersen on efficient development path; Company plans to start Phase 3 in mid-2025 – – Webcast and conference call for analysts and investors at 8:00AM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein

      1/7/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join th

      1/6/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

      12/20/24 7:51:37 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

      Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

      10/14/24 7:42:47 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics upgraded by TD Cowen

      TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform

      3/26/24 8:09:24 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care